Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101193 | 1.00 | ADRA2A (0.35) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL17798946 | 0.87 | NPC1 (0.35) | GRM1LMNAMAPTNPC1RAB9A | |
| SCHEMBL17798945 | 0.87 | NPC1 (0.35) | GRM1LMNAMAPTNPC1RAB9A | |
| SCHEMBL8173444 | 0.82 | MEN1 (0.35) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Uc 781 SCHEMBL29838161 | 0.81 | LMNA (0.42) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| Uc 781 SCHEMBL2670342 | 0.81 | LMNA (0.42) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL599255 | 0.79 | GRM1 (0.35) | GRM1LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30504230 | 0.79 | GRM1 (0.37) | GRM1LMNAMAPTNPC1RAB9A | |
| SCHEMBL25709709 | 0.75 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL3034633 | 0.73 | PLA2G7 (0.43) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861652-B2 | 2′ Fluoronucleosides | EMORY UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-9675632-B2 | Nucleoside and nucleotide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | EMORY UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| WO-2016033164-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9180138-B2 | 2′-fluoronucleosides | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9085599-B2 | 2′allene-substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8895531-B2 | 2′-fluoronucleoside phosphonates as antiviral agents | RFS PHARMA LLC (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2078029-B1 | ENANTIOMERICALLY PURE PHOSPHOINDOLE AS HIV INHIBITOR | IDENIX PHARMACEUTICALS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8575119-B2 | 2′-chloroacetylenyl substituted nucleoside derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-0986375-A2 | USE OF MKC-442 IN COMBINATION WITH OTHER ANTIVIRAL AGENTS | Triangle Pharmaceuticals Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000003998-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-01-27 | — | — | WO | disclosed |
| EP-0970078-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999066936-A1 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | EMORY UNIVERSITY (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999043691-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0874839-A1 | FURAN- AND THIOPHENECARBOTHIOAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE REPLICATION OF HIV-1 AND HIV-1 MUTANTS | UNIROYAL CHEMICAL COMPANY, Inc. (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998044913-A2 | COMPOSITIONS CONTAINING MKC-442 IN COMBINATION WITH OTHER ANTIVIRAL AGENTS | TRIANGLE PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998041522-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 1998-09-24 | — | — | WO | disclosed |
| US-5696151-A | Compounds useful for the inhibition of the replication of HIV-1 and HIV-1 mutants | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1997019940-A1 | FURAN- AND THIOPHENECARBOTHIOAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE REPLICATION OF HIV-1 AND HIV-1 MUTANTS | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1997-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | PNP, BCL3, NPC1 | ADRA2A 3542/4885ADRA2B 2888/4885ADRA2C 2768/4885 |
| US-20160058783-A1 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES | PCNA, ENTPD5, NME2 | ADRA2A 4459/4885ADRA2B 4281/4885ADRA2C 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.